Efficacy of Combined PD-1 Inhibitor and Bevacizumab in Unresectable Liver Metastasis of MSI-H Colorectal Cancer: A Case Report

Qifan Wang; Jie Zhong; Yi Wang; Jun Bao; Sheng Li; Liu Yang

doi:10.12659/AJCR.946757

10 January 2025 : Case report China

Efficacy of Combined PD-1 Inhibitor and Bevacizumab in Unresectable Liver Metastasis of MSI-H Colorectal Cancer: A Case Report

Unusual clinical course, Unusual or unexpected effect of treatment

Qifan Wang

^1ABCDEF, Jie Zhong^2ABCDEF, Yi Wang^1EF, Jun Bao^1AG*, Sheng Li^1ABEF, Liu Yang^1AG

DOI: 10.12659/AJCR.946757

Am J Case Rep 2025; 26:e946757

Authors information Article notes Copyright and License information

Introduction Case Report Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Figure 4. (A–E) Contrast-enhanced computed tomography (CT) showing multiple liver metastases at different times: (A) baseline (2018-03-16); (B) after first-line treatment (2018-06-25); (C) after 2 courses of second-line treatment (2018-08-24); (D) after about 1 year of second-line treatment (2019-06-13); (E) CT before liver tumor resection (2020-03-13); and (F) contrast-enhanced magnetic resonance imaging showing multiple liver metastases (2020-03-14).

Back to the Article

Efficacy of Combined PD-1 Inhibitor and Bevacizumab in Unresectable Liver Metastasis of MSI-H Colorectal Cancer: A Case Report

Your Privacy